基线CTX水平升高可预测唑来膦酸在提升中国骨质疏松患者腰椎骨密度方面的疗效增强
本研究纳入472例接受年度唑来膦酸治疗的中国原发性骨质疏松患者,按基线CTX水平分三组。基线CTX最高组(超过0.480 ng/ml)腰椎骨密度T值较参照组提升0.4单位,但髋部及股骨颈骨密度变化与基线CTX水平无显著关联。提示CTX水平可能有助于腰椎治疗选择,尚需进一步研究。
要点
- 472例中国骨质疏松患者按基线CTX水平分三组,均接受年度唑来膦酸治疗。
- 基线CTX最高组腰椎骨密度T值较参照组提升0.4单位,髋部及股骨颈无此关联。
- 基线CTX超过0.480 ng/ml与唑来膦酸提升腰椎骨密度疗效增强显著相关。
核心结论
- 在中国人群中,基线CTX水平升高(尤其超过0.480 ng/ml)与唑来膦酸提升腰椎骨密度疗效增强显著相关,但与髋部及股骨颈骨密度改善的关联较弱。
研究设计与样本
- 研究纳入至少两次住院并接受年度唑来膦酸治疗的原发性骨质疏松患者472例,按给药前基线CTX水平升序分为三组,采用方差分析比较组间骨密度变化,并使用广义估计方程分析基线CTX与治疗后骨密度变化的关系,统计分析采用SPSS 26.0。
主要发现
- 以第1组为参照,基线CTX最高的第3组腰椎T值提升0.4单位。
- 基线CTX水平与唑来膦酸治疗后髋部或股骨颈骨密度变化之间未观察到明显关系。
关键数值与推荐
- 基线CTX超过0.480 ng/ml与唑来膦酸提升腰椎骨密度疗效增强显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This study examined the link between baseline CTX levels and zoledronic acid's effectiveness in boosting bone density in osteoporosis patients. Among 472 Chinese patients, higher initial CTX levels correlated with greater lumbar spine bone density improvement after treatment. However, no such correlation was found for hip or femoral neck bones. This suggests CTX levels may aid in treatment selection for lumbar spine, though further research is needed. The findings have clinical implications for optimizing osteoporosis treatment. PURPOSE: To elucidate the correlation between baseline CTX levels and the therapeutic efficacy of zoledronic acid in augmenting bone mineral density (BMD) among individuals with osteoporosis. METHODS: This study studied patients diagnosed with primary osteoporosis who were hospitalized at least twice and received annual zoledronic acid therapy. Patients were stratified into three groups based on their initial CTX levels prior to zoledronic acid administration. ANOVA was employed to compare BMD alterations across the groups. Generalized estimating equations (GEE) were utilized to analyze the relationship between baseline CTX levels and subsequent BMD changes post-zoledronic acid treatment. Statistical analyses were conducted using SPSS version 26.0. RESULTS: A total of 472 patients were evaluated and categorized into three cohorts according to their initial CTX levels, arranged in ascending order. Notably, group 3, characterized by the highest initial CTX levels, demonstrated a significantly more pronounced increase in lumbar spine BMD compared to the other two groups. Specifically, when group 1 served as the reference, group 3 exhibited a 0.4-unit elevation in lumbar spine T-score. Conversely, no discernible relationship was observed between baseline CTX levels and BMD changes in the hip or femoral neck following zoledronic acid treatment. CONCLUSIONS: Our findings among a Chinese population indicate that elevated CTX levels, particularly exceeding 0.480 ng/ml, are notably associated with enhanced therapeutic efficacy of zoledronic acid in boosting lumbar spine BMD. However, this correlation appears less robust with respect to improvements in hip and femoral neck BMD.
引用
- Zhang Q, Gao W, Xu X, et al. Elevated baseline CTX levels predict enhanced therapeutic efficacy of zoledronic acid in augmenting lumbar spine bone mineral density among Chinese osteoporosis patients. Osteoporos Int. 2025. PMID: 40038109. doi:10.1007/s00198-025-07448-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。